stockrow
Friday 6 November 2026
Export SNOA’s income statement to Excel — free account
Sonoma Pharmaceuticals, Inc.
SNOA Healthcare Drug Manufacturers Specialty & Generic
Sonoma Pharmaceuticals, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $19.5 million, up 36.7% from fiscal 2025.
- Revenue
- +59.6%
- EPS
- +88.2%
- Free cash flow
- +69.3%
Quarter to June 2026, against a year earlier
1.12
0.05
+4.67%
Follow SNOA
Alert me
| Mar '17 | Mar '18 | Mar '19 | Mar '20 | Mar '21 | Mar '22 | Mar '23 | Mar '24 | Mar '25 | Mar '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 3 | 4 | 2 | 3 | 2 | 5 | 4 | 5 | 3 |
P/E ratio |
3.26 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.36 | 1.02 | 0.40 | 0.40 | 0.80 | 0.84 | 0.25 | 0.18 | 0.19 | 0.18 |
Altman Z-Score |
(3.62) | (9.65) | (15.73) | (16.19) | (14.63) | (12.75) | (15.47) | (17.82) | (19.15) | (18.52) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(11.17) | (23.10) | (36.60) | (38.60) | (36.06) | (29.40) | (34.87) | (40.45) | (44.32) | (44.40) |
P/Operating CF |
(11.25) | (5.57) | (2.79) | (2.02) | (10.05) | (7.63) | (1.36) | 15.49 | (28.61) | (6.91) |
Beneish M-Score |
2.72 | (2.99) | (1.67) | (1.88) | (2.98) | (2.70) | (1.93) | (3.22) | (4.09) | (1.69) |
P/B ratio |
1.42 | 1.11 | 0.73 | 1.29 | 2.77 | 1.22 | 0.42 | 0.38 | 0.62 | 1.16 |
Price to Tangible BV |
1.42 | 1.11 | 0.73 | 1.29 | 2.77 | 1.22 | 0.42 | 0.38 | 0.62 | 1.16 |
EV/Sales |
1.03 | 0.44 | 0.23 | 0.27 | 0.67 | 0.35 | 0.00 | (0.03) | (0.18) | 0.07 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.10 | 0.72 | 0.00 |
EV/Operating CF |
(1.62) | (0.59) | (0.37) | (1.04) | (3.71) | (1.03) | 0.01 | 0.18 | 29.08 | (0.33) |
EV/FCF |
(1.54) | (0.58) | (0.36) | (1.00) | (3.52) | (1.00) | 0.01 | 0.18 | 15.23 | (0.31) |
Quick Ratio |
5.95 | 3.56 | 2.00 | 1.62 | 1.72 | 1.68 | 1.72 | 1.62 | 1.86 | 1.02 |
Current Ratio |
6.89 | 4.98 | 3.48 | 2.60 | 3.18 | 2.82 | 3.71 | 3.37 | 3.09 | 2.50 |
Net Debt/EBITDA |
1.35 | 0.71 | 0.31 | 0.42 | 0.72 | 1.16 | 0.76 | 0.62 | 1.50 | 1.03 |
Debt/Assets |
1.32% | 2.11% | 2.31% | 4.92% | 12.72% | 4.29% | 2.66% | 2.19% | 0.00% | 0.00% |
Debt/Equity |
0.02 | 0.03 | 0.03 | 0.13 | 0.36 | 0.09 | 0.05 | 0.05 | 0.00 | 0.00 |
Asset Turnover |
0.65 | 0.75 | 1.13 | 1.24 | 1.26 | 0.75 | 0.76 | 0.82 | 1.01 | 1.41 |
Operating CF/Net income |
(0.88) | 0.87 | 0.99 | 1.39 | 0.86 | 0.84 | 1.19 | 0.50 | 0.03 | 1.24 |
Capex/Depreciation |
(1.59) | (0.38) | (0.22) | (0.66) | (0.79) | (0.74) | (2.15) | (0.01) | (0.58) | (1.38) |
Interest Coverage |
(4,324.67) | (354.72) | (341.15) | (461.87) | (215.56) | — | (285.62) | — | — | — |
| 58.75% | (77.96%) | (91.40%) | (41.06%) | (71.90%) | (72.35%) | (61.78%) | (68.51%) | (65.55%) | (84.60%) | |
| 47.24% | (64.16%) | (70.11%) | (22.81%) | (26.74%) | (30.07%) | (29.37%) | (31.22%) | (24.32%) | (22.96%) | |
ROIC |
(188.31%) | (156.51%) | (98.63%) | (174.36%) | (70.70%) | (174.46%) | (62.25%) | (88.18%) | 0.00% | (220.99%) |
Return on Tangible Assets |
45.03% | (101.41%) | (122.49%) | (41.77%) | (42.63%) | (46.53%) | (48.74%) | (52.59%) | (39.39%) | (41.90%) |
Average Days of Receivables |
59.99 | 33.68 | 66.98 | 80.89 | 54.98 | 69.57 | 70.73 | 83.06 | 57.02 | 47.23 |
Research and Development Expense of Revenue |
12.29% | 9.45% | 8.00% | 7.47% | 2.98% | 0.99% | 1.56% | 14.69% | 12.70% | 11.63% |
Selling, General and Administrative Expense of Revenue |
133.07% | 119.61% | 98.15% | 79.06% | 50.74% | 77.25% | 66.61% | 59.48% | 51.52% | 38.94% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
17.49% | 15.01% | 8.62% | 4.68% | 1.99% | 3.03% | 5.04% | 4.05% | 1.57% | 1.31% |
Graham Net Nets |
0.61 | 0.73 | 1.12 | 0.46 | 0.23 | 0.59 | 1.67 | 1.68 | 1.24 | 0.34 |
Graham Number |
2,850.68 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
30.69% | (84.23%) | (165.47%) | (45.65%) | (19.92%) | (45.39%) | (158.73%) | (476.70%) | (141.55%) | (88.73%) |
Free Cash Flow Yield |
(28.23%) | (74.42%) | (154.46%) | (66.24%) | (23.98%) | (41.20%) | (193.74%) | (101.96%) | (6.18%) | (115.00%) |
Revenue per Share |
545.74 | 661.03 | 410.61 | 242.60 | 186.66 | 95.16 | 78.21 | 27.99 | 11.51 | 11.60 |
Operating CF per Share |
(347.53) | (493.61) | (253.61) | (62.12) | (33.85) | (32.01) | (36.25) | (5.27) | (0.07) | (2.34) |
Capex per Share |
(16.77) | (7.42) | (2.16) | (2.79) | (1.79) | (1.03) | (1.59) | 0.00 | (0.06) | (0.11) |
Free Cash Flow per Share |
(364.30) | (501.03) | (255.78) | (64.91) | (35.64) | (33.04) | (37.84) | (5.27) | (0.14) | (2.45) |
Cash per Share |
743.02 | 399.44 | 79.85 | 49.95 | 42.28 | 55.73 | 22.51 | 6.87 | 4.33 | 1.42 |
Shareholders Equity per Share |
911.96 | 608.17 | 227.03 | 76.10 | 53.74 | 65.54 | 47.01 | 13.49 | 3.55 | 1.84 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
911.96 | 608.17 | 227.03 | 76.10 | 53.74 | 65.54 | 47.01 | 13.49 | 3.55 | 1.84 |
Free Cash Flow |
(8.56) | (12.63) | (11.82) | (4.80) | (3.56) | (4.38) | (6.42) | (2.40) | (0.17) | (4.12) |
Working Capital |
19.36 | 12.99 | 8.91 | 7.55 | 8.91 | 10.61 | 10.08 | 8.83 | 8.55 | 7.27 |
Capital Expenditures |
(0.39) | (0.19) | (0.10) | (0.21) | (0.18) | (0.14) | (0.27) | 0.00 | (0.08) | (0.19) |
Net Current Asset Value |
18.62 | 12.37 | 8.54 | 3.35 | 3.36 | 6.28 | 5.54 | 3.95 | 3.37 | 1.24 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.09 | 0.69 | 0.00 |
Capex to Sales |
0.03 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.00 | 0.01 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.20 | 0.43 | 0.62 | 0.85 | 0.63 | 0.58 | 0.26 | 0.48 | 0.61 | 0.45 |
Cash ROIC |
(21.82%) | (48.94%) | (81.43%) | (47.82%) | (30.96%) | (25.95%) | (52.51%) | (25.03%) | (1.72%) | (75.08%) |
Accounts Receivable Turnover |
7.09 | 9.14 | 7.56 | 4.81 | 5.50 | 4.84 | 5.33 | 4.66 | 5.57 | 8.21 |
Accounts Payable Turnover |
5.52 | 7.40 | 7.99 | 5.90 | 6.29 | 5.06 | 7.09 | 11.04 | 11.31 | 8.42 |
Inventory Turnover |
3.75 | 3.68 | 3.22 | 3.51 | 5.12 | 3.33 | 3.19 | 2.87 | 3.13 | 3.69 |
Average Days of Payables |
64.00 | 49.67 | 45.40 | 76.94 | 53.50 | 69.36 | 34.90 | 27.73 | 39.42 | 57.94 |
Days of Inventory on Hand |
113.27 | 111.87 | 123.32 | 81.18 | 76.51 | 112.56 | 118.61 | 124.21 | 120.59 | 110.01 |
Average Receivables |
1.81 | 1.82 | 2.51 | 3.73 | 3.39 | 2.61 | 2.49 | 2.74 | 2.57 | 2.38 |
Average Payables |
1.30 | 1.26 | 1.26 | 1.66 | 1.92 | 1.71 | 1.24 | 0.72 | 0.78 | 1.44 |
Average Inventory |
1.91 | 2.54 | 3.14 | 2.80 | 2.36 | 2.60 | 2.76 | 2.79 | 2.82 | 3.28 |
Average Assets |
19.63 | 22.33 | 16.83 | 14.50 | 14.77 | 16.92 | 17.54 | 15.49 | 14.22 | 13.83 |
Average Common Equity |
15.79 | 18.38 | 12.91 | 8.06 | 5.49 | 7.03 | 8.34 | 7.06 | 5.27 | 3.75 |
Columns are period end dates · fundamentals updated 26 Oct 2026